JP Morgan Chase
CMMB

JP Morgan Chase’s Chemomab Therapeutics CMMB Stock Holding History

JP Morgan Chase’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-295
Closed -$1.37K – 7432
2025
Q2 		$1.37K Buy
+295
New +$1.46K ﹤0.01% 6586
2024
Q4 		– Sell
-275
Closed -$1.73K – 7433
2024
Q3 		$1.73K Buy
+275
New +$1.54K ﹤0.01% 6638
2024
Q2 		– Hold
0
– – – 7282
2024
Q1 		– Hold
0
– – – 7328
2022
Q2 		– Sell
-188
Closed -$4K – 6510
2022
Q1 		$4K Buy
+188
New +$3.71K ﹤0.01% 6342
2021
Q3 		– Sell
-13
Closed -$1K – 6509
2021
Q2 		$1K Buy
+13
New +$1.27K ﹤0.01% 6236

Other funds holding CMMB

SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

JP Morgan Chase's CMMB Position: Q3 2025 in Review

JP Morgan Chase sold out of Chemomab Therapeutics (CMMB) in Q3 2025, closing a stake of 295 shares — an estimated $1.37K sold.

JP Morgan Chase first reported a position in CMMB in Q2 2021 and held it in 4 quarters. The position peaked at $4K in Q1 2022. 10 funds tracked by Wall St. Rank hold CMMB as of Q3 2025.

  • JP Morgan Chase reported no remaining Chemomab Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 295 Chemomab Therapeutics shares in Q3 2025, an estimated $1.37K.
  • JP Morgan Chase first reported a position in Chemomab Therapeutics in Q2 2021 and held it in 4 quarters.
  • JP Morgan Chase's Chemomab Therapeutics position peaked at $4K in Q1 2022.
  • 10 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.